Objectives We evaluated the efficacy and safety of dalbavancin in ABSSSI and 'other sites' infections' (OTA). Methods Observational study involving 11 Italian hospitals including patients that received >= 1 dose of dalbavancin in 2016-2019. The outcome was end-of-treatment efficacy and safety in ABSSSI and OTA in a real-life setting. Results 206 patients enrolled (males 50%, median age 62 [IQR 50-76] years), 60.2% ABSSSI, 39.8% OTA. 69.7% ABSSSIvs90.7% OTA (p = 0.003) and 46.3% ABSSSIvs37.2% OTA (p = 0.786) received previous and concomitant antibiotics, respectively. 82.5% reached clinical cure . Eleven (5.4%) patients had non-serious adverse events (AE). OTA patients showed longer hospitalization (13.5 days, 5.5-22vs3, 0-11.7; p<0.0001) and received longer previous (18 days, 9-30vs11, 7-19; p = 0.007)/concomitant antibiotic treatments (21 days, 14-52vs11, 8-14; p < 0.0001), compared to ABSSSI. ABSSSI and OTA showed similar efficacy (85.5%vs75%, p = 0.459) and safety (no AE: 81.5%vs64.3%, p = 0.258); efficacy was independent of previous/concomitant therapies. Conclusions Dalbavancin demonstrated a success rate of >80%, with similar efficacy/safety in ABSSSI and off-label indications. The preferential use of dalbavancin as second-line or combination therapy would seem to suggest the need for in-depth studies focused on its off-label use.

Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study) / F. Bai, C. Aldieri, A. Cattelan, F. Raumer, E. Di Meco, M. Moioli, F. Tordato, P. Morelli, F. Borghi, M. Rizzi, E. Van Hauwermeiren, F. Castelli, G. Migliorino, B. Menzaghi, G. Rizzardini, A. Saracino, A. Cascio, M. Puoti, A. d'Arminio Monforte, G. Marchetti. - In: EXPERT REVIEW OF ANTI-INFECTIVE THERAPY. - ISSN 1478-7210. - 18:12(2020 Dec 01), pp. 1271-1279.

Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study).

F. Bai
Primo
;
C. Aldieri
Secondo
;
A. d'Arminio Monforte
Penultimo
;
G. Marchetti
Ultimo
Writing – Review & Editing
2020-12-01

Abstract

Objectives We evaluated the efficacy and safety of dalbavancin in ABSSSI and 'other sites' infections' (OTA). Methods Observational study involving 11 Italian hospitals including patients that received >= 1 dose of dalbavancin in 2016-2019. The outcome was end-of-treatment efficacy and safety in ABSSSI and OTA in a real-life setting. Results 206 patients enrolled (males 50%, median age 62 [IQR 50-76] years), 60.2% ABSSSI, 39.8% OTA. 69.7% ABSSSIvs90.7% OTA (p = 0.003) and 46.3% ABSSSIvs37.2% OTA (p = 0.786) received previous and concomitant antibiotics, respectively. 82.5% reached clinical cure . Eleven (5.4%) patients had non-serious adverse events (AE). OTA patients showed longer hospitalization (13.5 days, 5.5-22vs3, 0-11.7; p<0.0001) and received longer previous (18 days, 9-30vs11, 7-19; p = 0.007)/concomitant antibiotic treatments (21 days, 14-52vs11, 8-14; p < 0.0001), compared to ABSSSI. ABSSSI and OTA showed similar efficacy (85.5%vs75%, p = 0.459) and safety (no AE: 81.5%vs64.3%, p = 0.258); efficacy was independent of previous/concomitant therapies. Conclusions Dalbavancin demonstrated a success rate of >80%, with similar efficacy/safety in ABSSSI and off-label indications. The preferential use of dalbavancin as second-line or combination therapy would seem to suggest the need for in-depth studies focused on its off-label use.
Gram-positive infections; acute bacterial skin and skin structure infections; second-generation lipoglycopeptide antibiotics; dalbavancin;
Settore MED/17 - Malattie Infettive
ago-2020
Article (author)
File in questo prodotto:
File Dimensione Formato  
Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections ABSSSIs and other infections in a real life.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 3.67 MB
Formato Adobe PDF
3.67 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/807582
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 11
social impact